Price vs. United Laboratories

The Court held that the Director of Patents, pursuant to Section 36 of Republic Act No. 165 and Section 35 of Presidential Decree No. 1263, has the statutory authority to unilaterally fix the terms and conditions of a compulsory license after a hearing when the parties fail to reach an agreement. The Court further held that a compulsory license may be granted over an entire patent even if only one claim is contested, provided the licensee pays adequate royalties, and that a licensee's capability to use the patented invention may be established at any time during the hearing, not solely at the filing of the petition.

Petitioners Barry John Price, et al., were the owners-assignees of Philippine Patent No. 13540 for a pharmaceutical compound with histamine H₂ blocking activity (aminoalkyl furan derivatives). On October 1, 1982, respondent UNILAB, a leading domestic drug manufacturer, filed a petition with the Philippine Patent Office for a compulsory license to use the patented compound in its own medicines, alleging the invention related to public health and that UNILAB possessed the capability to use it.

Petitioners owned Philippine Patent No. 13540 for a pharmaceutical compound (aminoalkyl furan derivatives). UNILAB filed a petition for compulsory license, claiming the invention related to medicine and public health and that it had the capability to use the compound. After a hearing, the Director of Patents granted the license, setting a 2.5% royalty on net sales and other conditions. The Court of Appeals affirmed this decision. UNILAB had been engaged in drug manufacturing for thirty years and possessed the necessary equipment and expertise.

• Petitioner argued that the Director of Patents erred in unilaterally determining the license terms without affording the parties an opportunity to negotiate freely.
• Petitioner contended that UNILAB did not possess the legally required capability to use the patented compound at the time it filed its petition.
• Petitioner asserted that the compulsory license should have been limited to the specific claim (Claim 45) that was controverted, rather than the entire patent.
• Petitioner maintained that the 2.5% royalty rate was unfair and constituted an undue deprivation of property rights.

• Respondent countered that the Director of Patents acted within his statutory authority under R.A. No. 165 and P.D. No. 1263 to fix the license terms in default of an agreement.
• Respondent argued that it had the requisite capability to use the patented compound, as evidenced by its long history as a leading drug manufacturer with the necessary equipment and expertise.
• Respondent contended that the royalty rate of 2.5% was just and reasonable, falling well within the statutory maximum of 5% of net wholesale price.
• Respondent noted that identical terms and conditions had been prescribed in numerous other compulsory license cases.

• Procedural Issues: Whether the Court of Appeals erred in upholding the Director of Patents' unilateral determination of the compulsory license's terms and conditions without prior negotiation between the parties.
• Substantive Issues:
  1. Whether UNILAB possessed the legally required capability to use the patented compound.
  2. Whether the Director of Patents properly granted a compulsory license over the entire patent when only one claim was controverted.
  3. Whether the 2.5% royalty rate was just and reasonable.

• Procedural: The Court affirmed the Director of Patents' authority. Because the parties failed to reach an agreement, the Director was expressly authorized under Section 36 of R.A. No. 165 and Section 35 of P.D. No. 1263 to fix the terms and conditions of the compulsory license after a hearing. The Court found no abuse of discretion.
• Substantive:
  1. The Court upheld the finding that UNILAB possessed the requisite capability. The Director's factual finding was supported by substantial evidence of UNILAB's 30-year experience, equipment, and technological expertise. The Court ruled that capability proven to exist during the hearing was sufficient, even if acquired after the petition's filing.
  2. The Court held that the license was properly granted over the entire patent. There is no law requiring a compulsory license to be limited to a specific embodiment or claim. Since the patented compound (ranitidine hydrochloride) was covered by the general and sub-generic claims, a license for only one claim would not be fully comprehensive. The patentee would receive royalties on all sales, thus preventing any deprivation of property without just compensation.
  3. The Court found the 2.5% royalty rate reasonable. The rate was within the statutory maximum of 5% (per Section 35-B of R.A. 165, as amended) and was fixed after considering the evidence. The Director enjoys sound discretion in setting the rate, and a presumption of regularity attaches to official acts.

• Authority of the Director of Patents to Fix Compulsory License Terms — Under Philippine patent law (R.A. 165, as amended by P.D. 1263), if the Director finds a case for a compulsory license is made out and the parties cannot agree on terms, the Director has the statutory duty and authority to fix the terms and conditions of the license after a hearing. The Court applied this to uphold the Director's order setting the royalty rate and other conditions.
• Scope of a Compulsory License — A compulsory license may be granted over an entire patent even if the petition contests only one specific claim, provided the license is "appropriate" and the patentee receives adequate royalties. The Court applied this principle, noting that the compound was covered by multiple claims and that limiting the license would be impractical and not prejudicial to the patentee.
• Adequacy of Royalty Rate — The royalty for a compulsory license must be "adequate" and "commensurate with the extent to which the invention is worked," but shall not exceed 5% of the net wholesale price. The Court deferred to the Director's discretion in setting a 2.5% rate, finding it reasonable and consistent with precedent.

• "The terms and conditions of the compulsory license were fixed by the Director of Patents after a hearing and careful consideration of the evidence of the parties and in default of an agreement between them as to the terms of the license. This he is authorized to do under Section 36 of Republic Act No. 165..." — This passage underscores the statutory basis for the Director's authority to act when parties disagree.
• "The Director's finding that UNILAB has the capability to use the patented compound... is a factual finding which is supported by substantial evidence, hence, the Court of Appeals did not commit a reversible error in affirming it." — This reaffirms the standard of review for factual findings of administrative agencies.
• "There is no law requiring that the license be limited to a specific embodiment of the invention, or, to a particular claim." — This establishes the principle that a compulsory license can cover the entire patent right.
• "In any event, since the petitioner will be paid royalties on the sales of any products the licensee may manufacture using any or all of the patented compounds, the petitioner cannot complain of a deprivation of property rights without just compensation." — This provides the rationale for allowing a broad license, tying it to the constitutional protection against taking property without compensation.

• Philippine Nut Industry, Inc. vs. Standard Brands, Inc., 65 SCRA 575 — Cited for the principle that factual findings of administrative agencies, when supported by substantial evidence, are binding on the courts.
• Sy Ching vs. Gaw Liu, 44 SCRA 143 — Cited for the same principle regarding the conclusiveness of factual findings supported by substantial evidence.
• United Laboratories, Inc. vs. Boehringer Ingelhelm, GMBH (IPC 929, July 27, 1981) and other cited IPC cases — Cited as precedents demonstrating that identical terms and conditions (including the 2.5% royalty) had been prescribed in a "good number" of prior compulsory license cases, indicating consistency and reasonableness.

• Section 36, Republic Act No. 165 (The Patent Law) — Provides the Director of Patents the authority to order the grant of a compulsory license and to fix its terms and conditions in default of an agreement between the parties.
• Section 35, Presidential Decree No. 1263 (Amending R.A. 165) — Reinforces the Director's duty to grant a license and fix its terms within 180 days if a case is made out and the parties do not agree.
• Section 35-B(3), R.A. 165 as amended by P.D. 1263 — Establishes that royalties for a compulsory license must be adequate, commensurate with the working of the invention, and shall not exceed 5% of the net wholesale price. Provides the statutory ceiling within which the Director exercises discretion.

N/A — The decision was rendered per curiam with Justices Narvasa, Cruz, Gancayco, and Medialdea concurring. No separate concurrences are noted in the text.

N/A — The decision was unanimous. No dissenting opinions are noted in the text.